Merus receives Buy rating and $90 price target from Alliance Global Partners

Alliance Global Partners initiated coverage of Merus (MRUS) with a Buy rating and $90 price target.

Alliance Global Partners has initiated coverage on Merus N.V. (MRUS) with a Buy rating and a price target of $90. The biotechnology company, which specializes in the development of bispecific antibody therapeutics, has been gaining attention from investors and analysts alike.

According to the latest Form 13F filing, Aberdeen Group plc significantly increased its stake in Merus during the first quarter, owning approximately 0.25% of the company's stock worth $7.24 million [1]. This substantial investment reflects a growing interest in Merus's potential as a clinical-stage immuno-oncology company.

In addition to Aberdeen Group plc, several other large investors have also modified their holdings in Merus. Geode Capital Management LLC, Wells Fargo & Company MN, Raymond James Financial Inc., Adage Capital Partners GP L.L.C., and Voya Investment Management LLC have all increased their stakes in the biotechnology company [1].

Merus reported a loss of $2.23 EPS for the quarter, which was significantly below analysts' expectations, alongside a revenue of $8.83 million. Despite the earnings miss, the company's pipeline, which includes Zenocutuzumab (MCLA-128) for the treatment of metastatic breast cancer and castration-resistant prostate cancer, remains a key focus for investors [1].

The stock has experienced a 1.6% decline in mid-day trading on Monday, hitting $66.3950. The company's 50-day moving average price is $59.91, and its 200-day moving average price is $50.50. Merus has a market capitalization of $5.02 billion, a price-to-earnings ratio of -12.07, and a beta of 1.09 [1].

Alliance Global Partners' Buy rating and $90 price target reflect a positive outlook on Merus's growth prospects. The company's innovative pipeline and strong investor interest suggest that Merus could be a promising investment opportunity for those seeking exposure to the immuno-oncology sector.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-has-724-million-stock-position-in-merus-nv-mrus-2025-08-21/
[2] https://www.cnn.com/markets/stocks/MRUS